Cargando…

Biomarkers for Chronic Lung Allograft Dysfunction: Ready for Prime Time?

Chronic lung allograft dysfunction (CLAD) remains a major hurdle impairing lung transplant outcome. Parallel to the better clinical identification and characterization of CLAD and CLAD phenotypes, there is an increasing urge to find adequate biomarkers that could assist in the earlier detection and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verleden, Stijn E., Hendriks, Jeroen M.H., Lauwers, Patrick, Yogeswaran, Suresh Krishan, Verplancke, Veronique, Kwakkel-Van-Erp, Johanna M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875844/ https://www.ncbi.nlm.nih.gov/pubmed/35980878 http://dx.doi.org/10.1097/TP.0000000000004270

Ejemplares similares

Minimally Invasive Surgery in Non-Small Cell Lung Cancer: Where Do We Stand?
por: Berzenji, Lawek, et al.
Publicado: (2023)

Use of High Dose Corticosteroids Reversed COVID-19 Associated ARDS in a Patient Listed for Lung Transplantation
por: Verplancke, V., et al.
Publicado: (2022)

The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review
por: Berzenji, Lawek, et al.
Publicado: (2021)

From Macroscopy to Ultrastructure: An Integrative Approach to Pulmonary Pathology
por: Verleden, Stijn E., et al.
Publicado: (2022)

Soluble CD59 is a Novel Biomarker for the Prediction of Obstructive Chronic Lung Allograft Dysfunction After Lung Transplantation
por: Budding, Kevin, et al.
Publicado: (2016)

Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer
por: Allaeys, Toon, et al.
Publicado: (2022)

Surgical Management of Stage IIIA Non-Small Cell Lung Cancer
por: Van Schil, Paul E., et al.
Publicado: (2017)

Mechanistic differences between phenotypes of chronic lung allograft dysfunction after lung transplantation
por: Suwara, Monika I, et al.
Publicado: (2014)

Cancer Biomarkers: Are We Ready for the Prime Time?
por: Mishra, Alok, et al.
Publicado: (2010)

Quantitative CT Correlates with Local Inflammation in Lung of Patients with Subtypes of Chronic Lung Allograft Dysfunction
por: Ram, Sundaresh, et al.
Publicado: (2022)

Good’s syndrome and COVID-19: case report and literature review
por: Berzenji, Lawek, et al.
Publicado: (2022)

Safety and Feasibility of Lung Cancer Surgery under the COVID-19 Circumstance
por: Berzenji, Lawek, et al.
Publicado: (2022)

Plasma biomarkers for neurodegenerative disorders: ready for prime time?
por: Balogun, Wasiu G., et al.
Publicado: (2023)

Radiologic and histologic correlates of early interstitial lung changes in explant lungs
por: Verleden, Stijn E., et al.
Publicado: (2023)

Early Identification of Chronic Lung Allograft Dysfunction: The Need of Biomarkers
por: Tissot, Adrien, et al.
Publicado: (2019)

OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening
por: Deben, Christophe, et al.
Publicado: (2022)

Potential novel biomarkers for chronic lung allograft dysfunction and azithromycin responsive allograft dysfunction
por: Veraar, Cecilia, et al.
Publicado: (2021)

Pulmonary metastasectomy in colorectal carcinoma
por: Beckers, Paul, et al.
Publicado: (2021)

Commentary: Almost ready for prime time
por: Wei, Lawrence M.
Publicado: (2020)

Tumor-Infiltrating Lymphocytes in Head and Neck Cancer: Ready for Prime Time?
por: Almangush, Alhadi, et al.
Publicado: (2022)

REBOA: is it ready for prime time?
por: Doucet, Jay, et al.
Publicado: (2017)

Biomarkers for early diagnosis of AKI in the ICU: ready for prime time use at the bedside?
por: Honore, Patrick M, et al.
Publicado: (2012)

Thin-section Computed Tomography findings before and after azithromycin treatment of neutrophilic reversible lung allograft dysfunction
por: de Jong, Pim A., et al.
Publicado: (2011)

Biomarkers in Coronary Artery Bypass Surgery: Ready for Prime Time and Outcome Prediction?
por: Parolari, Alessandro, et al.
Publicado: (2016)

Circulating Tumor Cells as Biomarkers for Renal Cell Carcinoma: Ready for Prime Time?
por: Couto-Cunha, Anabela, et al.
Publicado: (2022)

Is pocket ultrasound ready for prime time?
por: Galen, Benjamin T
Publicado: (2012)

Radiotherapy for HCC: Ready for prime time?
por: Bang, Andrew, et al.
Publicado: (2019)

CGM in the Hospital: Is It Ready for Prime Time?
por: Buschur, Elizabeth O., et al.
Publicado: (2022)

Counterpoint: Clinical Islet Transplantation: Not Ready for Prime Time
por: Khan, Mahfuzul H., et al.
Publicado: (2009)

Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?
por: Khan, Tahsin M., et al.
Publicado: (2020)

Glucocorticoid therapy for trauma - ready for prime time?
por: Aleti, Venkata S, et al.
Publicado: (2012)

CT colonography screening: ready for prime time?
por: Heiken, Jay P.
Publicado: (2009)

Robotic assisted adrenalectomy: Is it ready for prime time?
por: Teo, Xin Ling, et al.
Publicado: (2016)

Are Seizure Detection Devices Ready for Prime Time?
por: Van Ness, Paul C.
Publicado: (2019)

Telemedicine in pediatric otolaryngology: Ready for prime time?
por: Schafer, Austin, et al.
Publicado: (2020)

Zinc–air batteries: are they ready for prime time?
por: Zhang, Jie, et al.
Publicado: (2019)

Commentary: Interesting…maybe not ready for prime time?
por: Chang, Stephanie H.
Publicado: (2021)

Fluorescence optical imaging: ready for prime time?
por: Ohrndorf, Sarah, et al.
Publicado: (2021)

“Artificial Intelligence” for Pharmacovigilance: Ready for Prime Time?
por: Ball, Robert, et al.
Publicado: (2022)

Liquid biopsies, are we ready for prime time?
por: Normanno, Nicola, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ojirsvanmrdg0637acfr721kh4